The invention provides (+)-α-dihydrotetrabenazine succinate salt.
Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-α-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome.
The invention further provides a method for preparing the (+)-α-dihydrotetrabenazine succinate salt.